Defining predictive values using three different platelet function tests for CYP2C19 phenotype status on maintenance...

Area of Science:

• Pharmacogenomics
• Cardiovascular Medicine
• Clinical Chemistry

Background:

• Clopidogrel response is influenced by CYP2C19 genetic variations.
• CYP2C19 loss-of-function (LOF) alleles are associated with increased platelet aggregation and cardiovascular risk post-clopidogrel therapy.
• Accurate prediction of CYP2C19 phenotype is vital for optimizing antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI).

Purpose of the Study:

• To determine specific cut-off values for three different platelet aggregometry assays.
• To predict CYP2C19 loss-of-function (LOF) allele status in Korean patients undergoing PCI.
• To guide the clinical application of antiplatelet therapy based on genetic profiles.

Main Methods:

• Enrolled 244 Korean patients receiving clopidogrel and aspirin post-drug-eluting stent implantation.
• Assessed platelet reactivity using light transmittance aggregometry (LTA), multiple electrode aggregometry (MEA), and VerifyNow P2Y12 (VN) assays.
• Determined CYP2C19 genotype using polymerase chain reaction (PCR) and snapshot methods.

Main Results:

• The frequency of CYP2C19 LOF allele carriers was 58.6%.
• Established cut-off values: LTA ≥ 48% (10 µM ADP-induced), VN > 242 PRU, and MEA ≥ 37 U for identifying LOF allele carriers.
• Reported varying correlations between assays: LTA vs. VN (r=0.69), LTA vs. MEA (r=0.56), and VN vs. MEA (r=0.42).

Conclusions:

• The study provides validated cut-off values for LTA, VerifyNow, and MEA assays to detect CYP2C19 LOF alleles.
• These findings aid in predicting clopidogrel response and managing antiplatelet therapy in Korean PCI patients.
• Optimizing antiplatelet therapy based on pharmacogenetic information can improve cardiovascular outcomes.